Skip to Content
  • Drug Development Costs Revisited

    A recent paper on drug development costs did not impress me. But if possible, it impressed Matthew Herper at Forbes even less. That’s the one where the au… Read More
  • Whole Classes of Things

    We all know about target-based drug discovery. Enough biology has been learned that we think that Protein X is operating at a crucial stage in the development o… Read More
  • Alnylam Breaks Through

    As a pioneer in RNAi therapeutics, Alnylam has really had some ups and downs over the years (some of them chronicled on this blog). Today would be one of the &# Read More
  • It Costs More Than This

    Here’s another paper on the cost to develop a new drug, a topic about which, I’m convinced, debate will never end. This one is designed as a respons… Read More
  • AMPK: Time To Think Hard

    AMP-activated protein kinase, now that’s an enzyme for you. It sits at the center of a cell’s metabolic switchboard, and if you’re talking abo… Read More
  • How Long, Oh Lord, How Long?

    Here we have the prototypical slow summer day. So I’m going to use this one to throw a question out to the readership: those of you in preclinical drug di… Read More
  • A Long Journey to the Capsid

    There’s a fine article at C&E News on Gilead’s capsid inhibitor for HIV. For those not into virology, the capsid is the protein coat that viruse… Read More
  • Following Up

    Here’s a question that I’m not sure if there’s a general answer to: if you’re putting together a drug discovery portfolio, what percenta… Read More
Page 1 of 5412345...102030...Last »